Nurse Practitioner in Pennsauken, NJ Accepting Medicare

11 Nurse Practitioner nurses found. Showing 1 - 11

Cynthia Carter Alston, MSN, NP Nurse Practitioner - Adult Health Medicare: Accepting Medicare Assignments Practice Location: 5101 N Park Dr, Pennsauken, NJ 08109 Phone: 856-665-8844    Fax: 856-665-1888

Ramona Hernandez, NP Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 6705 Park Ave, Pennsauken, NJ 08109 Phone: 856-662-0017

Christine Kelly, APN-C Nurse Practitioner - Gerontology Medicare: Not Enrolled in Medicare Practice Location: 2475 Mcclellan Ave, Pennsauken, NJ 08109 Phone: 856-675-3355

Candice Ogline, RN, APN,C Nurse Practitioner - Adult Health Medicare: Medicare Enrolled Practice Location: 2475 Mcclellan Ave, Pennsauken, NJ 08109 Phone: 856-675-3660    Fax: 856-675-3659

Uchenna Joseph Ekeabu, APN, PMHNP-BC Nurse Practitioner - Psych/Mental Health Medicare: Medicare Enrolled Practice Location: 4928 Laurel Ave, Pennsauken, NJ 08109 Phone: 856-263-0752

Susan M Midili, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 7665 Maple Ave, Pennsauken, NJ 08109 Phone: 856-665-9520    Fax: 856-665-6684

Ms. Harrislyn J Saywah, Nurse Practitioner - Psych/Mental Health Medicare: Not Enrolled in Medicare Practice Location: 651 Cove Rd, Pennsauken, NJ 08110 Phone: 856-313-4183

Mrs. Valerie Dawn Fulton, APN Nurse Practitioner - Women's Health Medicare: Accepting Medicare Assignments Practice Location: 6981 N Park Dr Ste 300a, Pennsauken, NJ 08109 Phone: 856-854-4524

Mrs. Natalie Walker, CRNP Nurse Practitioner - Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2562 Hadley Dr, Pennsauken, NJ 08109 Phone: 215-888-3832

Victoria T Ellis, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2475 Mcclellan Ave, Suite B201, Pennsauken, NJ 08109 Phone: 856-330-6300    Fax: 856-330-6305

Amanda Rader, MSN, FNP-C Nurse Practitioner - Family Medicare: Medicare Enrolled Practice Location: 6705 Park Ave, Pennsauken, NJ 08109 Phone: 856-662-0017

News Archive

Dr. Nancy Chiaravalloti of Kessler Foundation receives Alumni Achievement in Science award

Nancy (Donofrio) Chiaravalloti, PhD, of Kessler Foundation received the Alumni Achievement in Science award from her alma mater, Muhlenberg College at the Alumni Association luncheon on September 13th.

Phase 1/2 clinical trial of TRC105 therapy initiated for patients with castrate-resistant prostate cancer

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that the National Cancer Institute has initiated a Phase 1/2 clinical trial of TRC105 therapy for patients with castrate-resistant prostate cancer.

Penn researchers find effective way to inhibit inflammatory response during kidney dialysis

Frequent kidney dialysis is essential for the approximately 350,000 end-stage renal disease (ESRD) patients in the United States. But it can also cause systemic inflammation, leading to complications such as cardiovascular disease and anemia, and patients who rely on the therapy have a five-year survival rate of only 35 percent. Such inflammation can be triggered when the complement cascade, part of the body's innate immune system, is inadvertently activated by modern polymer-based dialysis blood filters.

Study represents new use of bone marrow transplantation

Researchers at Fred Hutchinson Cancer Research Center have opened a clinical trial to test the theory that giving a patient a new immune system can cure severe cases of Crohn's disease, a chronic inflammatory condition of the gastrointestinal tract.

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

Read more Medical News

› Verified 1 days ago